An evaluation of sotorasib for the treatment of patients with non–small cell lung cancer with KRASG12C mutations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An evaluation of sotorasib for the treatment of patients with non–small cell lung cancer with KRASG12C mutations

Published:2022-09-22 Issue:14 Volume:23 Page:1569-1575
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Strohbehn Garth W.¹²³,Sankar Kamya⁴,Qin Angel³,Kalemkerian Gregory P.³

Affiliation:

1. Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA

2. Division of Medical Oncology, LTC Charles S Kettles VA Medical Center, Ann Arbor, MI, USA

3. Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA

4. Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2134777

Reference49 articles.

1. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers

2. Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States

3. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation

4. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

5. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Most Disruptive Near-Term Use of AI in Cancer Care: Patient Empowerment Through Software Agents;AI in Precision Oncology;2024-08-30

2. Sotorasib as first-line therapy in patients with advanced non-small cell lung cancer with KRAS gene mutations combined with brain metastases: a case report;AME Case Reports;2024-04

3. US Government Payer–Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?;Journal of Clinical Oncology;2023-05-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3